Non Hodgkinâ€™s Lymphoma
In our live webTV show we offer advice and support for patients living with this devastating blood cancer
Show date: Wednesday 15th September 2010
Show time: 12.30pm
Non Hodgkinâ€™s Lymphoma (NHL) is a cancer of the lymphatic system[i] which, according to Cancer Research UK, was responsible for over 4,000 deaths in the UK in 2008 alone.[ii] Despite the fact that more than 10,000 people in the UK are diagnosed with NHL every year,[ii] the disease has so far failed to become a public priority.
Whilst treatment options are increasing, the UKâ€™s five-year survival rate remains around 50% for NHL.ii When compared with other common cancers such as breast cancer which has five year survival rates of approximately 80%,[iii] the need for greater awareness and increased treatment options to improve outcomes for patients with the disease becomes apparent.
The good news is that on Wednesday 15th September a treatment that is already available for patients in the US, Germany and Switzerland will be launched in the UK offering a life-line to hundreds of patients with slow-growing NHL in the UK, for whom other licensed treatments have failed. [iv],[v],[vi]
Whatâ€™s more, Wednesday 15th September is World Lymphoma Awareness Day, so to help raise the profile of this devastating disease, our live web TV show will be answering your questions and offering advice and information about NHL. We will also be discussing the treatments that are now available for people living with this disease.
So, if your life has been touched by NHL, or you simply want to find out more about the signs and symptoms of the disease, log onto the show where Dr Rob Hicks, Dr Andy Davies and Sally Penrose will be offering their advice and providing answers to all of your questions.
Click here to submit questions before the show.
For more information visit http://www.lymphomas.org.uk
Macmillan website: Accessed June 2011
[v] Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab â€“ refractory indolent and transformed non-Hodgkinâ€™s lymphoma results from a phase II multicenter, single-agent study. J Clin Oncol 2008;26:204-10
Kahl B, et al Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkinâ€™s lymphoma. Cancer 2010; 106-14